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Abstract
Tumor invasion and metastasis is a highly compli-
cated, multi-step phenomenon. In the complex event 
of tumor progression, tumor cells interact with base-
ment membrane and extracellular matrix components. 
Proteolytic enzymes (proteinases) are involved in the 
degradation of extracellular matrix, but also in cancer 
invasion and metastasis. The four categories of pro-
teinases (cysteine-, serine-, aspartic-, and metallopro-
teinases) are named and classified according to the 
essential catalytic component in their active site. We 
and others have shown that proteolytic enzymes play a 
major role not only in colorectal cancer (CRC) invasion 
and metastasis, but also in malignant transformation 
of precancerous lesions into cancer. Tissue and serum-
plasma antigen concentrations of proteinases might be 
of great value in identifying patients with poor prog-
nosis in CRC. Our results, in concordance with others 
indicate the potential tumor marker impact of protein-
ases for the early diagnosis of CRC. In addition, pro-
teinases may also serve as potential target molecules 
for therapeutic agents.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Tumor invasion and metastasis is a highly 
complex phenomenon. Proteolytic enzymes (protein-
ases) are involved in the degradation of extracellular 
matrix, in colorectal cancer (CRC) invasion and me-
tastasis, as well as in the malignant transformation of 
colorectal adenomas. Tissue and serum-plasma antigen 
concentrations of proteinases are strong prognostic 
factors in CRC and may have tumor marker impact for 
early diagnosis. Proteolytic enzymes may serve as po-
tential target molecules for CRC therapy. Their use in 
combination with established chemotherapeutic strate-
gies might have the potential to become a valuable on-
cological treatment modality. 
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MECHANISMS OF TUMOR 
PROGRESSION
Tumor invasion and metastasis is a highly complicated, 
multi-step phenomenon. The multistep metastatic pro-
cess requires the actions of  several genes and involves the 
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initial transforming event (i.e., oncogene activation), pro-
liferation of  transformed cells and the ability of  tumor 
cells to avoid destruction by immune-mechanisms. Fur-
thermore, it comprises of  nutrition supply to the tumor 
mass by the release of  tumor angiogenesis factors, cancer 
cell local invasion and destruction of  extracellular matrix 
(ECM) components, epithelial mesenchymal transition 
(EMT), shedding from primary tumor, intravasation, ar-
rest, extravasation and colonization at a preferential site 
resulting in the formation of  a secondary tumor (distant 
metastases)[1-9]. 
Chronic and persistent inflammation can predispose 
to carcinogenesis and contribute to cancer development. 
Cancer-associated inflammation includes infiltrating 
leucocytes, cytokines, chemokines, growth factors and 
matrix-degrading enzymes. Inflammatory conditions can 
initiate oncogenic transformation and epigenetic and 
genetic changes in malignant cells. In essence, two inter-
related pathways connect inflammation and cancer: (1) 
genetic alterations (including chromosomal amplifica-
tion, activation of  oncogenes and inactivation of  tumor-
suppressor genes) leading to neoplastic transformation; 
and (2) presence of  tumor-infiltrating leukocytes that are 
prime regulators of  cancer-related inflammation. The 
integration of  these two pathways activates transcription 
factors and finally creates a tumor-associated inflamma-
tory milieu[10-19]. 
BASEMENT MEMBRANE, 
EXTRACELLULAR MATRIX AND CANCER 
CELLS
All normal or pre-invasive tumor epithelia are physically 
segregated from vascular structures within the stroma by 
the basement membrane (BM). The BM consists of  lam-
inins, type Ⅳ collagen and surrounding epithelial cells. 
The tumor stroma is comprised of  ECM, non-malignant 
cells, and the signalling molecules they produce. During 
tumor invasion and metastasis, tumor cells are interacting 
with the BM and the ECM. The disruption of  the BM 
and the ECM is an essential pre-requisite for cancer cell 
invasion and metastasis. Interaction of  tumor cells with 
the BM and ECM comprises of  three steps: attachment, 
matrix dissolution and migration. The first step is tumor 
cell attachment to the matrix. The attachment is mediated 
by tumor cell surface receptors, when tumor cells bind to 
BM surface. This process involves specific glycoproteins 
such as fibronectin, type Ⅳ collagen and laminin. In the 
second step tumor cells directly secrete degradative en-
zymes or induce the host to produce proteolytic enzymes 
to degrade ECM. The matrix lysis takes place in a highly 
localized region close to the tumor cell surface. Dur-
ing the third step (migration), cancer cells are propelled 
across the BM and stroma through the zone of  matrix 
proteolysis. Invasion of  ECM is accomplished by rever-
beration of  these three steps[3,6,9,20-27].
GENERAL ROLES OF PROTEOLYTIC 
ENZYMES IN CANCERS
The four categories of  proteinases (cysteine-, serine-, as-
partic-, and metalloproteinases) are named and classified 
according to the essential catalytic component (usually 
an amino acid) in their active site[3,28]. Table 1 summa-
rises the four categories and some general properties of  
each group. Proteolytic enzymes play a major role in the 
breakdown and reconstitution of  ECM in a variety of  
physiological and pathological processes, such as protein 
turnover, tissue remodeling, wound repair, angiogenesis, 
destructive diseases, inflammatory disorders as well as 
tumor invasion and metastasis (Table 2). Tumor cells 
have been shown to produce and release several proteo-
lytic enzymes, which are thought to be involved in tumor 
invasion and metastasis. Proteolytic enzymes are also fre-
quently produced by surrounding stromal cells, including 
fibroblasts and inflammatory cells. It has been proposed 
that these proteolytic enzymes cause degradation or dis-
ruption of  BM and ECM components allowing the in situ 
cancer cells to migrate into the adjacent stroma or to dis-
seminate to distant organ. It is commonly accepted that 
progression from in situ to invasive or metastatic cancer 
is caused by proteolytic enzymes (proteinases) produced 
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Table 1  Categories and main properties of proteolytic 
enzymes
Property Cysteine 
proteases
Serine 
proteases
Aspartic 
proteases
Metallo 
proteases
Active site Cysteine Serine Aspartic acid Zinc
Optimum pH 7-9 3-7 2-4 5-9
Location Lysosomes Intra-
extracellular
Lysosomes Intra-
extracellular
Examples Cathepsins Elastase Pepsinogen 
Ⅰ-Ⅱ
Collagenase
B, L, C, H Trypsin Cathepsins 
D, E
Stromelysin
PA: uPA, tPA Gelatinase Matrilysin
Inhibitors Cystatin Antitrypsin Unknown TIMP
Antithrombin 
Ⅲ
PAI
PA: Plasminogen activators; uPA: Uroinase-type plasminogen activator; 
tPA: Tissue-type plasminogen activator; PAI: Plasminogen activator 
inhibitor; TIMP: Tissue inhibitor of metalloproteinases.
Table 2  General roles of proteolytic enzymes in cancers
Degradation or disruption of basement membrane and extracellular 
matrix
Produce components which allow the in situ cancer cells to disseminate 
to distant organ
Formation of a complex microenvironment that promotes malignant 
transformation  
Activation of growth factors, adhesion molecules
Suppression of tumor cell apoptosis
Destruction of chemokine gradients
Modulation of antitumor immune reactions
Dual and complex role in angiogenesis
by tumor cells that increase linearly in concentration with 
tumor progression[3,6,9,29-31]. 
The impact of  proteolytic enzymes in tumor progres-
sion is much more complex than that derived from their 
direct degradative action on BM and ECM components. 
Now they are known to have functions that extend far 
outside matrix remodeling. Proteolytic processing of  
bioactive molecules by proteinases contributes to the 
formation of  a complex microenvironment that pro-
motes malignant transformation. Proteolytic enzymes can 
contribute to tumor growth either directly or indirectly 
via growth factors such as transforming growth factor-β 
(TGF-β), basic fibroblast growth factor (bFGF) or, 
insulin-like growth factor (IGF). Proteinases also act on 
other non-matrix substrates (e.g., chemokines, adhesion 
molecules, apoptotic mediators, angiogenic factors) that 
yield the critical cellular responses that are essential for 
tumor growth and progression. Proteolytic enzymes are 
also associated with a variety of  escape mechanisms that 
tumor cells develop to avoid immune response including 
chemokine cleavage and regulation of  chemokine mo-
bilization. Tumor cells produce chemokines, cytokines, 
and the extracellular matrix metalloprotease inducer 
(EMMPRIN), which in turn activates tumor-cell invasion. 
During angiogenesis, proteolytic enzymes can have both 
a pro-angiogenic impact, by releasing matrix-bound pro-
angiogenic factors such as TGF-β, bFGF, triggering the 
angiogenic switch during carcinogenesis and facilitating 
vascular remodeling and neovascularization at distant 
sites during metastasis, and also may have anti-angiogenic 
role, by cleaving the ECM components into anti-ang-
iogenic factors[32-36]. 
Cysteine and serine proteinases
It has been observed that cysteine proteinases [cathep-
sin B (CATB) and cathepsin L (CATL)], play a crucial 
role in the destruction of  various elements of  the cell-
surrounding ECM. The serine proteinase urokinase-type 
plasminogen inhibitor (uPA) is also involved in many 
protein degrading processes. uPA seems to promote 
invasion through a plasmin mediated degradation of  
ECM proteins. Active uPA catalyzes the conversion from 
plasminogen to plasmin, which is a potent activator of  
several metalloproteinase proenzymes, such as pros-
tromelysin, procollagenase, and progelatinase B. Beyond 
its direct proteolytic capacity, CATB has also been shown 
to activate the prourokinase-type plasminogen activator 
(pro-uPA). The tissue-type plasminogen activator (TPA) 
is a key enzyme in the fibrinolytic cascade. Plasminogen 
activators (PA) are controlled by plasminogen activator 
inhibitors, which are members of  the serine proteinase 
inhibitors (serpin) family. The PA inhibitor type-1 (PAI-1) 
under normal physiologic conditions inhibits both uPA 
and TPA. The exact role of  PAI-1 in tumor biology 
is complex: PAI-1 may represent a specific protein of  
transformed malignant tissue; may protect cancer tissue 
against the proteolytic degradation triggered by the tu-
mor on surrounding normal tissue; and finally, PAI-1 has 
a role in angiogenesis playing a part in tumor spread[37-45].
Cathepsins and components of  the plasminogen 
activator and inhibitor system have been demonstrated 
in various malignant tissues, e.g., breast cancer[46-48], lung 
cancer[49,50], head and neck cancer[51], ovarian cancer[52] or 
gastric cancer[53-56] and might therefore be useful as a di-
agnostic tool. 
With respect to the gastrointestinal (GI) tract, we have 
previously shown that cysteine and serine proteinases are 
widely distributed in GI tissues, being implicated in proc-
esses of  GI tissue remodelling, angiogenesis, wound heal-
ing, inflammation, may have a role not only in the process 
of  esophageal or gastric cancer invasion, but also in the 
progression of  GI precancerous lesions into cancer[57-61]. 
Several studies, along with our own, have also pointed to 
the prognostic value of  cysteine and serine proteinases 
for survival, for instance, in gastric cancer[56,58,59,62,63], pan-
creatic cancer[64], or hepatocellular carcinoma[65]. 
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) family consists of  
26 members of  homologous zinc-dependent endo-
peptidases. The expression of  MMPs is induced by a 
variety of  external stimuli such as cytokines and growth 
factors, including interleukins, interferons, vascular en-
dothelial growth factor, fibroblast growth factor (FGF), 
tumor necrosis factor-alpha (TNF-α) or TNF-β, and 
EMMPRIN. MMPs play an important role in the deg-
radation of  ECM components, are crucial for tumor 
growth, invasion and metastasis. MMPs are synthesized 
as inactive zymogens, which are then activated by either 
other MMPs or by serine proteinases. Based on substrate 
specificities and sequence homology, MMPs can be 
classified as gelatinases, collagenases, stromelysins and 
matrilysins. MMPs are responsible for cleaving all of  the 
major ECM proteins[66-74]. 
We and others have shown that MMPs, particularly 
type Ⅳ collagenase MMP-9 (gelatinase B), are essential 
in the process of  tumor invasion and metastasis, as well 
as in the remodeling and inflammatory processes in 
IBD[75-82].
MMPs have also been considered as potential di-
agnostic and prognostic biomarkers in many types and 
stages of  GI cancer[83-85].
Tissue inhibitors of matrix metalloproteinases
MMPs activity is specifically inhibited by natural in-
hibitors, called tissue inhibitors of  metalloproteinases 
(TIMPs). Currently, four different TIMPs have been 
characterized in humans (TIMP-1, -2, -3 and -4). The bal-
anced interaction of  MMPs with TIMPs regulates ECM 
homeostasis. The imbalance between MMPs and TIMPs 
is an essential step in the development of  malignancies. 
TIMPs might display a dual influence on tumor progres-
sion: either beneficial by inhibiting MMPs and impairing 
angiogenesis or harmful by facilitating cancer cell genera-
tion, tumor growth and metastasis. The sensitive balance 
between MMPs and TIMPs is essential for many physi-
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the process of  tumor invasion and metastasis. We have 
also shown that CATL, uPA and PAI-1 have a major 
prognostic impact in patients with CRC[107].
Serum and plasma concentrations of cysteine and ser-
ine proteinases in CRC 
Given the lack in the literature of  a comparison of  the 
behavior of  cysteine proteinase CATB and serine pro-
teinase uPA in the same experimental setting in different 
GI tumors, in a previous study we have surveyed the pos-
sible clinical impact of  serum CATB and plasma UPA 
antigen in CRC, gastric cancer, hepatocellular carcinoma, 
pancreatic cancer, and colorectal adenomas[61]. We have 
demonstrated that preoperative serum CATB and plasma 
uPA antigen concentrations were significantly higher 
in GI tract cancers overall than those found in control 
non-cancer patients, thus confirming the relevance of  
cysteine and serine protease-dependent mechanisms in 
GI cancers. We have also further confirmed that serum 
CATB and uPA plasma levels were elevated in patients 
with CRC[108-111]. In addition, we have shown that serum 
CATB and plasma uPA did show a significant increase 
in advanced CRC stage. We have also demonstrated for 
the first time that antigen levels of  CATB and uPA were 
significantly higher in blood samples of  patients with 
colorectal adenomas as compared to controls. Further-
more, we have found significantly higher CATB and uPA 
antigen levels in patients with tubulovillous adenomas 
with high-grade dysplasia (HGD) compared to those 
with tubular adenomas with low-grade dysplasia (LGD). 
Thus taken together, the data from blood samples with 
previous results obtained in colorectal tissues confirm 
that a concomitant activation of  serine (CATB) and uPA 
may be involved in the progression from premalignant 
colorectal adenomas into CRC[112,113].
Some other studies have also suggested the potential 
impact of  cysteine or serine proteases as tumor mark-
ers in CRC[108-111]. Given the lack in the literature for a 
comparison of  the tumor marker utility and possible 
prognostic relevance of  cathepsins (CATB, CATL) and 
the uPA/PAI-1 system in the same experimental setting, 
we have surveyed the behavior of  CATB, CATL, uPA, 
PAI-1 in CRC and compared it with the commonly used 
gastrointestinal tumor markers CEA and CA 19-9, and 
then evaluated any correlation between these parameters 
and the clinico-pathological staging of  CRC[114]. In this 
study, we have demonstrated the potential tumor marker 
utility and prognostic relevance of  cysteine and serine 
proteinases for patients with CRC. We have also shown 
the concomitant activation of  these systems in CRC. At 
the time of  clinical presentation, proteinases were more 
sensitive indicators of  diagnosis than the most com-
monly used markers CEA and CA 19-9. When protein-
ases, CEA and CA 19-9 were used as single markers, we 
found that their sensitivity was more indicative of  CRC 
than CEA or CA 19-9. The simultaneous determina-
tion of  several markers led to a higher sensitivity in our 
group of  CRC patients: PAI-1 combined with CATB or 
ological processes in the gut[6,86-91].
We have recently demonstrated that not only MMPs 
but also TIMPs may contribute to the inflammatory and 
remodeling processes in IBD and serum TIMP-1 might 
be useful as additional biomarker in the assessment of  
IBD activity[82].  
IMPACT OF PROTEOLYTIC ENZYMES IN 
COLORECTAL CANCER 
colorectal cancer (CRC) is the third most common ma-
lignant neoplasm worldwide. CRC is the second most 
common newly diagnosed cancer and the second most 
common cause of  cancer death in the European Union 
(EU). Despite the advances in screening, diagnosis, and 
treatment, the overall long-term outcome of  curatively 
resected patients has not significantly changed in the last 
decades, the five-year survival rate being approximately 
60%. More than a half  of  CRCs are still diagnosed only 
when the disease involves regional or distant organs, and 
these patients are candidates for systemic chemotherapy. 
The prognosis of  CRC is determined primarily by TNM 
staging and pathomorphological parameters. Further-
more, therapeutic strategies for chemotherapy are based 
on traditional prognostic systems. For risk stratification, it 
would be useful for clinicians to have new and more effi-
cient preoperative tumor markers and prognostic indica-
tors available, for instance to better identify patients who 
need adjuvant or neoadjuvant treatment[92-97]. 
We review hereinafter the prognostic value and po-
tential tumor marker impact of  a number of  proteolytic 
enzymes. We also discuss proteinases as potential target 
molecules for therapeutic agents Table 3 summarises the 
clinical significance of  proteolytic enzymes in CRC.  
Tissue expression of cysteine and serine proteinases in 
CRC
Cathepsins or components of  the plasminogen activator 
and inhibitor system have been demonstrated in color-
ectal cancer tissue and might therefore be useful as diag-
nostic tools[98-100]. Some of  the studies also showed that 
cathepsins or some of  PAs also have a prognostic sig-
nificance for patients with CRC[98-106]. In a former study 
we have demonstrated the simultaneous up-regulation of  
both cysteine and serine proteinases in CRC confirming 
their role in colorectal tumor biology and particularly in 
Table 3  Clinical significance of proteolytic enzymes in 
colorectal cancer
Role in colorectal tumor biology, in the process of tumor invasion and 
metastasis
Role in malignant transformation of colorectal precancerous conditions 
and lesions
Potential diagnostic tool
New and independent prognostic factors
Potential tumor marker impact for early diagnosis
Potential target molecules for therapeutic agents
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uPA was superior compared to the combinations of  all 
other markers. In addition, the sensitivity of  CEA or CA 
19-9 in combination with a proteinase antigen level was 
more indicative for CRC than CEA or CA 19-9 alone. 
In this study increased serum or plasma proteinase con-
centrations significantly correlated with advanced tumor 
stage. In a univariate survival analysis high serum CATB, 
CATL and plasma PAI-1 antigen levels identified patients 
with shorter survival and those who were at higher risk 
of  death. In addition, PAI-1 and CATB were proved as 
independent predictor variables in a multivariate statisti-
cal analysis. We also confirmed that cysteine and serine 
proteinases were significantly higher in blood samples of  
patients with colorectal adenomas compared to controls, 
suggesting that these proteinases may be involved in the 
malignant transformation of  colorectal adenomas[114].
Tissue MMPs and TIMPs in CRC
The behavior of  MMPs and TIMPs in CRC has recently 
been extensively reviewed by our own group[115]. Several 
studies have shown that the expression of  several MMPs 
and TIMPs are enhanced in CRC. In an immunohisto-
chemical study we have demonstrated that tissue expres-
sion of  one particular MMP, MMP-9 was significantly 
higher in moderately (G2) and poorly (G3) differentiated 
tumors than in well differentiated (G1) cancers, as well 
as in advanced Dukes stages compared with Dukes stage 
A[116]. Some recent studies have confirmed that tissue 
MMP-9 can be considered as an independent prognostic 
marker in CRC[117-120]. In addition, it has been demonstrat-
ed that not only MMP-9, but also tissue expressions of  
other MMPs and TIMPs have strong prognostic impact 
in CRC[121-126].  
MMPs and TIMPs also play a role in malignant trans-
formation from colorectal adenomas to CRC. Our group 
in concordance with others has shown that tissue ex-
pression of  MMP-9, MMP-2, TIMP-1 and TIMP-2 were 
significantly higher in advanced versus non-advanced 
adenomas, suggesting that MMPs and TIMPs might be 
markers for early colorectal carcinogenesis. The abil-
ity of  MMPs and TIMPs to distinguish adenomas with 
HGD from adenomas without HGD may be of  clinical 
value in predicting additional cancer risk for an individu-
al patient[116,127-130]. 
Serum and plasma MMPs and TIMPs in CRC
The diagnostic, prognostic and tumor marker impact of  
serum-plasma MMPs and TIMPs in CRC has been exten-
sively studied. We have demonstrated that serum antigen 
concentrations of  MMP-2, MMP-7, MMP-9 as well as 
TIMP-1 and TIMP-2 were significantly higher in patients 
with CRC than in healthy controls. All examined param-
eters were significantly higher in patients with CRC than 
in patients with adenomas. Higher antigen concentrations 
of  MMPs and TIMPs significantly correlated with preop-
erative tumor stage. The data from blood samples con-
firmed previous results of  tissue expressions concluding 
that MMPs and their inhibitors TIMP-1 and TIMP-2 play 
an important role not only in CRC invasion and metasta-
sis, but they are also activated in premalignant colorectal 
adenomas[82].  
Several recent studies confirmed that high preop-
erative serum or plasma MMP-2, MMP-9 and mainly 
TIMP-1 antigen levels are strong predictive factors for 
poor prognosis in patients with CRC[131-137]. 
The potential tumor marker role of  MMPs and 
TIMPs has also been extensively studied. It has been 
demonstrated that MMP-9 and TIMP-1 have significant 
potential as biomarkers in CRC. Diagnostic sensitivity 
of  MMP-9 and TIMP-1 was consistently higher as com-
pared with the conventional biomarkers (CEA or CA 
19-9)[131,138-140]. 
It has also been proposed that TIMPs can predict in-
dividual response to chemotherapy and could be consid-
ered as an additional tool for monitoring chemotherapy 
in CRC[141-144].
One of  the greatest challenges in CRC management 
is to predict the outcome of  each patient so that we 
can determine who will really benefit from intensified 
adjuvant therapy. The classical TNM staging system re-
lied heavily on the exact extent of  cancer at the time of  
diagnosis and is greatly predictive in stage Ⅰ and stage 
Ⅳ tumors. However, it is less informative for patients 
including stage Ⅱ and stage Ⅲ CRC. After curative sur-
gery, stage Ⅲ CRC patients experience 50% chance of  
developing recurrence. It is well documented that the 
overall survival rate of  stage Ⅲ CRC could clearly ben-
efit from adjuvant chemotherapy. In contrast, the role of  
adjuvant chemotherapy for stage Ⅱ CRC is still contro-
versial, despite the 20% recurrence in this group. We and 
others have suggested that proteolytic enzymes could 
constitute useful independent markers in addition to the 
TNM staging system for the intermediate groups includ-
ing stage Ⅱ and stage Ⅲ CRC. Proteolytic enzymes may 
help to identify patients who are more likely to have 
disease relapse and high risk of  death, thus those who 
are potential candidates to receive aggressive adjuvant 
chemotherapy[107,119,145-147]. 
On the other hand, taken into consideration that pro-
teolytic enzymes may have a crucial role not only in the 
invasive process of  CRC, but also in the progression of  
precancerous conditions and lesions into cancer, quantifi-
cation of  proteinases might be useful to identify patients 
at higher risk for progression to cancer, who could be 
subjected to a more strict follow-up protocol. 
PROTEOLYTIC ENZYMES AS POTENTIAL 
TARGET FOR CANCER THERAPY
The accumulated evidence strongly supports the concept 
of  the use of  cysteine proteinases (cathepsins) and serine 
proteinases (uPA-PAI system) as targets for cancer ther-
apy. It has been suggested that cathepsin inhibition rep-
resents a potential therapeutic strategy for the treatment 
of  cancer. Cathepsins inhibition seems to reduce invasion 
and metastasis, but there is concern that selective cathep-
Herszényi L et al . Proteolytic enzymes in colorectal cancer
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sin inhibition induces compensatory activity by other 
cathepsins. The combination of  cathepsin inhibition with 
conventional chemotherapy seems to be more effective 
and has yielded more consistent clinical results. Future 
research should be focused on the exact mechanisms and 
clinical effects of  this combination treatment[148-151]. 
The multifunctionality of  the uPA-uPAR-PAI-1 sys-
tem in cancer spotlighted serine proteinases to become 
potential targets for anticancer treatment. In addition, 
uPA system is also increasingly being recognized as a 
candidate target for gene therapy in cancer[152-159]. Several 
strategies, including the use of  ribozymes, DNAzyme, 
antisense oligodeoxynucleotides, uPA inhibitors, soluble 
uPAR, catalytically inactive uPA fragments, the interac-
tions of  uPAR with integrins and transmembrane recep-
tors, synthetic peptides and synthetic hybrids are under 
study, as they all interfere with the activity of  uPA or 
uPAR in tumor cells. Many clinical studies are ongoing 
and some uPA-related compounds have reached Phase Ⅱ 
clinical trials. 
Several therapeutic MMP inhibitors (MMPIs) have 
also been developed to target MMPs. Various natural 
compounds have been identified as inhibiting MMPs. 
In addition, several generations of  synthetic MMPIs 
were tested in phase Ⅲ clinical trials in humans, includ-
ing peptidomimetics, non-peptidomimetic inhibitors or 
tetracycline derivates, targeting MMPs in the extracel-
lular space. Other strategies of  MMP inhibition involve 
small interfering and antisense RNA technology[160-165]. In 
contrast to their promising effect in preclinical models, 
most of  these agents unfortunately failed in clinical trials, 
thus they are yet not available for routine use. The use of  
broad-spectrum MMPIs may lead to undesired clinical 
consequences as a result of  the wide range of  MMPs that 
are inhibited. In addition, toxic side effects, such as mus-
culoskeletal syndrome, have limited drug efficiency.
The ADAMs is also a family of  potential new targets 
for cancer therapy. ADAMs (a disintegrin and metallo-
proteinase) are members of  a zinc-dependent family of  
matrix metalloproteinases. Preclinical findings suggest 
that selective ADAM inhibitors might be novel antican-
cer agents. ADAMs inhibitors may be particularly use-
ful in treating cancers that depend on HER or TNF-α-
mediated signalling[166-169].
One of  the major challenges for the future is the de-
velopment of  monoclonal antibodies or inhibitors that 
are specific for certain MMPs, showing no cross-reaction 
with other MMPs with improved pharmacokinetic prop-
erties and selectivity. In addition, their use in combination 
with established chemotherapeutic strategies might have 
the potential to become valuable oncological treatment 
modalities[161,170-176].
CONCLUSION
Proteolytic enzymes play a sophisticated role in cancer 
development and progression due to their abilities to de-
grade various substrates. However, the role of  proteolytic 
enzymes in tumor progression is much more complex 
than that derived from their direct degradative action 
on BM and ECM components. Proteinases may have a 
crucial role not only in the invasive process of  CRC, but 
also in the progression of  precancerous conditions and 
lesions to CRC. Proteolytic enzymes could constitute ef-
fective independent prognostic markers additive to TNM 
staging system in CRC. Their determination might be 
useful to identify patients at higher risk for progression 
to cancer, who could be subjected to a more strict endo-
scopic follow-up protocol. 
It has recently been demonstrated in experimental 
settings that a newly developed near-infrared bioactivable 
probe (MMPSense) that reports the activity of  a broad 
array of  MMP isoforms detects both polypoid and non-
polypoid early colorectal adenomas with a high specifi-
city[177]. Future studies will focus on the use of  such fluo-
rescent probes combined with colonoscopy to identify 
neoplastic lesions based on their molecular “fingerprint” 
(i.e., proteinase enzymatic activity) rather than solely on 
their morphologic properties. The ability to detect non-
polypoid lesions using this fluorescent probe alone or in 
combination with other molecular probes may offer new 
future perspectives for colorectal screening. In addition, 
it might also serve as a potential strategy for the pharma-
codynamic monitoring of  targeted therapy. The pharma-
cological targeting of  CRC by the development of  a new 
generation of  effective and selective proteinase inhibitors 
is another emerging area of  research. 
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